When exchanging research materials with other institutions, it is important to understand the context in which these research materials are shared. If our university`s research material is shared with another organization that uses these materials for a research project of its own conception, where our university is neither intellectual nor practical, this transfer would most likely be as an outgoing MTA. The term „cooperation“ can mean different things to different people. From the office of Sponsored Programs perspective, collaboration occurs when we share our research materials with another entity and work together on a jointly developed project. The agreement chosen for the transfer of research materials is chosen on the basis of cooperation with the recipient institution and a large number of other factors. It is important that the purpose of the MTA and the purpose of using the samples and associated data be clearly described in the text. This effectively creates the limits of what can and cannot be done with materials. It can be done cross-sectionally more generally (for example. B is the goal of the transmission for pathogen characterization studies), whereby a separate section in the proximity of the beginning of the contract could suffice. 12) „informed prior consent,“ an agreement between a BIO member and a supplying party, establishing that the BIO member provided the providing party with information that met the requirements of Section III of these guidelines regarding a regulated genetic resource to which the BIO member had access. 4. To reach an agreement with the supplier on the conditions for the collection, handling and use of physical samples of regulated genetic resources, including, among other things, the distribution of the benefits from the use of these samples and the measures governing the handling or transmission of these samples.
4.2. The [transfer] [and the post, for which the purchaser acts as agent] returns samples of materials [and genetic resources or other materials produced from these samples] transferred pursuant to Article 3 of this agreement, or these genetic samples and resources or other materials are destroyed, such as the [transferor] when the [transferor] completes the uses covered in paragraph 1 of this article, unless necessary to meet the patent disclosure requirements. [Identify physical samples of regulated genetic resources that need to be transferred.] Risk management should be proportionate to the nature and likelihood of benefits: institutional contract staff should assess the existence or likelihood of the following risk categories against the likely benefits of the institution and/or its researchers, and use MTAs or simpler agreements accordingly. First, the risks relate to safety in the use of materials; ensure, for example, that scientifically quality materials are not used in human research or that materials are used in accordance with ethical standards. A second category of risk is legal: the inappropriate use of reagents may result in legal action by victims against entities; Third parties may claim that the material violates their intellectual property rights or that the materials provided are not of the quality claimed by the distributor. A third category of risk is reputation: MTAs may require adequate recognition of the author or distributor archives in subsequent publications or other research results, in order to promote the reputation of the source and provide a measure of the value of the material. The final category of risk is that third parties have misappropriated the credit or financial compensation that should be paid to the material writer: MTAs may restrict the distribution of reagents or materials to third parties to ensure that users return to the author to access materials in accordance with its terms or limit the commercial use of materials.